598 related articles for article (PubMed ID: 31190104)
1. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Oguma J; Ozawa S; Koyanagi K; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K
Esophagus; 2019 Oct; 16(4):395-401. PubMed ID: 31190104
[TBL] [Abstract][Full Text] [Related]
2. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
Yasuda T; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Doki Y
Ann Surg Oncol; 2015 Aug; 22(8):2599-607. PubMed ID: 25524011
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.
Sugimura K; Miyata H; Shinno N; Ushigome H; Asukai K; Yanagimoto Y; Hasegawa S; Takahashi Y; Yamada D; Yamamoto K; Nishimura J; Motoori M; Wada H; Takahashi H; Yasui M; Omori T; Ohue M; Yano M
Oncology; 2019; 97(6):348-355. PubMed ID: 31461716
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis.
Nabeya Y; Ochiai T; Matsubara H; Okazumi S; Shiratori T; Shuto K; Aoki T; Miyazaki S; Gunji Y; Uno T; Ito H; Shimada H
Dis Esophagus; 2005; 18(6):388-97. PubMed ID: 16336610
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
Lyu X; Huang J; Mao Y; Liu Y; Feng Q; Shao K; Gao S; Jiang Y; Wang J; He J
J Surg Oncol; 2014 Dec; 110(7):864-8. PubMed ID: 24976079
[TBL] [Abstract][Full Text] [Related]
9. Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma.
Hiraki Y; Kimura Y; Imano M; Kato H; Iwama M; Shiraishi O; Yasuda A; Shinkai M; Makino T; Motoori M; Yamasaki M; Miyata H; Satou T; Satoh T; Furukawa H; Yano M; Doki Y; Yasuda T
Surg Today; 2021 Jan; 51(1):118-126. PubMed ID: 32596796
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
[TBL] [Abstract][Full Text] [Related]
11. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H
World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603
[TBL] [Abstract][Full Text] [Related]
12. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907).
Yokota T; Ando N; Igaki H; Shinoda M; Kato K; Mizusawa J; Katayama H; Nakamura K; Fukuda H; Kitagawa Y
Oncology; 2015; 89(3):143-51. PubMed ID: 25895447
[TBL] [Abstract][Full Text] [Related]
14. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
[TBL] [Abstract][Full Text] [Related]
16. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
[TBL] [Abstract][Full Text] [Related]
17. Potential of Baseline Computed Tomography to Predict Long-Term Survival of Patients With Locally Advanced Esophageal Cancer Treated With Preoperative Chemotherapy: A Retrospective Cohort Study.
Wang ZL; Chen Y; Li XT; Chen KN; Sun YS
Medicine (Baltimore); 2016 May; 95(18):e3583. PubMed ID: 27149488
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
Nagai Y; Yoshida N; Baba Y; Harada K; Imai K; Iwatsuki M; Karashima R; Koga Y; Nomoto D; Okadome K; Ishimoto T; Imamura Y; Watanabe M; Baba H
Dig Endosc; 2020 Jan; 32(1):39-48. PubMed ID: 31120560
[TBL] [Abstract][Full Text] [Related]
19. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
Chen J; Yin W; Yao H; Gu W
Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Hatogai K; Fujii S; Kojima T; Daiko H; Kadota T; Fujita T; Yoshino T; Doi T; Takiguchi Y; Ohtsu A
J Surg Oncol; 2016 Mar; 113(4):390-6. PubMed ID: 27100024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
